San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will present a virtual corporate overview at the Sequire Cannabis Investor Conference and Planet Microcap Showcase next week. Details are as follows:
To read the full press release from Skye Bioscience, Inc., click here.
This headline brief is meant to help you stay on the pulse of your favorite cannabis-related companies.
Every day, The Daily Marijuana Observer seeks to keep stakeholders informed with as much of the latest news possible to keep you informed of any catalysts that may impact the companies you care about. Be sure to subscribe to cannabis stock updates here so you never miss an update.
Get Real-Time Updates from MJobserver.com
